



Villanova University Investigator

Qianhong Wu, Ph.D., Professor, College of Engineering, Department of Mechanical Engineering, Director of the Cellular Biomechanics and Sports Science Laboratory (CBMSS)

Background and Unmet Need

One of the important indicators of cardiovascular (CV) health is the structural integrity of arterial walls. One well-known method for assessing the physical state of the arterial wall is the noninvasive and relatively inexpensive brachial artery Flow-Mediated Dilation (BAFMD) test, in which blood flow through the brachial artery is obstructed temporarily (for about five minutes) using a pressure cuff wrapped around the upper arm, causing the artery to become almost completely closed. The cuff is then suddenly deflated, allowing the flow to rush back in while the dilating artery is monitored until full recovery, using an ultrasound scanner^{i,ii}. FMD metrics have been proposed in the past as potential cardiovascular health indicators. Correlations have been found linking abnormal FMD results with many underlying conditions and risk factors directly affecting cardiovascular diseaseⁱⁱⁱ and health^{iv,v,vi}.

Despite the critical role of FMD in evaluating cardiovascular diseases (CVDs), there is a significant lack of understanding of the fundamental biophysics governing the FMD process, which prevents it from being an effective and pervasive diagnostic tool for cardiovascular diseases.

Opportunity

Villanova University scientist Qianhong Wu has developed a novel method to assess the results of a BAFMD test, including a system and device that evaluate the output and results of an FMD process. It produces a diagnostic tool that overcomes the previous issues of interpreting an FMD test.

There is significant potential for the tool to be integrated into an ultrasound system and enable new diagnostic methods. Ultrasound already is used widely in cardiology as an inexpensive, noninvasive diagnostic tool. The global CV ultrasound market was valued at \$1.3 billion USD in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.7% from 2021 to 2028. The increase in CVD and a rise in preventative screening is expected to be the main stimulant of market growth. This invention could enable a novel diagnostic paradigm for ultrasound manufacturers to differentiate their offerings to cardiologists and other medical practitioners^{vii}.

In addition to enabling a more nuanced risk assessment of CVDs and other health issues that have already been found to correlate with abnormal FMD, another avenue where this invention could exhibit great potential is monitoring the progress of COVID long haulers. This is borne out by recent evidence^{viii} that SARS-CoV-2 has been associated with leaky vessels, pointing to a compromised glycocalyx layer, and endothelial function, the evolution of which the model underlying this invention is well-suited to detect.

Finally, there is potential for the invention as a clinical trials support tool. The ability to easily and non-invasively track longitudinal progression of arterial health could be useful for CVD clinical trials. The CVD drug market is expected to reach \$63.96B USD by 2026^{ix}, however there are concerns about the pipeline of promising candidates. CVD drug trials cost approximately six times that of average trials for other indications^x, with much of that cost associated with challenges in evidence generation^{xi}. A new, non-invasive, and inexpensive tool for CVDs could significantly reduce the price of developing new CVD drugs.

Unique Attributes

- Easily understood readout of a BAFMD response using a novel physics-based model.
- The method's sensitivity to anatomical variabilities, even within the same subject, could enable longitudinal tracking of individuals.

Clinical Applications

- Diagnostic assessment of cardiovascular diseases.
- Diagnostic monitoring of COVID long haulers.

Stage of Development

Pre-Clinical.

Intellectual Property

US Patent Application Published May 2022 as US 2022/0165420 A1.

Licensing and Collaboration Opportunity

Villanova University is seeking a licensee to commercialize the invention for diagnostic purposes in the treatment of cardiovascular diseases and / or monitoring of COVID long haul patients.

INSTITUTIONAL CONTACT

Amanda M. Grannas, Ph.D.
VP & Chief Research Officer
+1 610.519.4881
amanda.grannas@villanova.edu

L2C PARTNERS CONTACT

Merle Gilmore, MBA
+1 610.662.0940
gilmore@l2cpartners.com

Alex Togli, MS
+1 610.937.1067
toglia@l2cpartners.com

ⁱ Bchara Sidnawi, Zhen Chen, Chandra Sehgal, Qianhong Wu. Characterization of arterial flow mediated dilation via a physics-based model. *Journal of the Mechanical Behavior of Biomedical Materials*, Volume 107, 2020.

ⁱⁱ Bchara Sidnawi, Zhen Chen, Chandra Sehgal, Sridhar Santhanam, Qianhong Wu. On the modeling of mechanotransduction in flow-mediated dilation. *Journal of the Mechanical Behavior of Biomedical Materials*, Volume 120, 2021.

ⁱⁱⁱ McCully, K.K., 2012. Flow-mediated dilation and cardiovascular disease. *J. Appl. Physiol.* 112, 1957–1958.

^{iv} Birk, G.K., et al., 2012. Brachial artery adaptation to lower limb exercise training: role of shear stress. *J. Appl. Physiol.* 112, 1653–1658.

^v Pyke, K.E., Tschakovsky, M.E., 2005. The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. *J. Physiol.* 568, 357–369.

^{vi} Kaźmierski, M., Michalewska-Włodarczyk, A., Krzych, Ł.J., Tendera, M., 2010. Diagnostic value of flow mediated dilatation measurement for coronary artery lesions in men under 45 years of age. *Cardiol. J.* 17, 288–292.

^{vii} Cardiovascular Ultrasound Market Size, Share & Trends Analysis Report By Technology (Doppler, 3/4D), By Display (Color, B/W), By End-use (Hospitals, Ambulatory Care Centers), By Type, And Segment Forecasts, 2021 – 2028. Grandview Research.

^{viii} Veluswamy, P.; Wacker, M.; Stavridis, D.; Reichel, T.; Schmidt, H.; Scherner, M.; Wippermann, J.; Michels, G. The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications. *Viruses* 2021, 13, 1346.

^{ix} Cardiovascular Drugs Market Size is Projected to Reach USD 63.96 Billion at CAGR to 3.8% by 2026. *Fortune Business Insights*.

^x Cardiovascular disease market set to grow very slowly to \$146.4 billion by 2022, GBI Research. *Cardiovasc J Afr.* 2016;27(5):293.

^{xi} Warner et. Al. Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials. *Circulation: Cardiovascular Quality and Outcomes.* 2020;13:e006606.